Explore

CME2020

Scripps New Treatments in Chronic Liver Disease 2020 CME - San Diego

Hilton San Diego Resort and Spa, 1775 East Mission Bay Drive, San Diego, California, 92109, United States
20 - 22 March 2020
The conference ended on 22 March 2020

Important Dates

Abstract Submission Deadline
19th March 2020

About CME2020

Nationally renowned speakers will provide an update on commonly encountered problems in the treatment of liver disease.

Topics

Gastroenterology, Science, health and medicine

Call for Papers

This CME conference will review new medications and therapies that are now available, or will soon be available, and discuss their comparative values. The results of trials and real world data using oral drugs to treat chronic viral hepatitis B and C, non-alcoholic fatty liver diseases, primary biliary cirrhosis, primary sclerosing cholangitis, hepatocellular carcinoma and complications of end-stage liver disease including thrombocytopenia will be reviewed in detail. New Treatments in Chronic Liver Disease is a comprehensive yet concise program for updating physicians on these and other commonly encountered problems in the treatment of liver diseases. New treatments which have been reported for both Primary Biliary Cholangitis (PBC) and Primary Sclerosing Cholangitis (PSC) will be discussed by Dr. Kris Kowdley from the Swedish Liver Center in Seattle, WA. We also have invited Dr. Constantine J. Karvellas, Assistant Professor, Division of Gastroenterology, Department of Critical Care Medicine at the University of Alberta to act as our William S. Haubrich Memorial Lecturer on the topic of Acute Liver Failure. The course will also review alcoholic liver disease and NASH, which have now surpassed chronic hepatitis C as the leading indications for liver transplantation in the United States. The first FDA-approved therapy for NASH is anticipated in 2020 and the data supporting this FDA submission will be updated as well as the latest abstracts from AASLD 2019 on NASH. We have also invited a world-recognized expert on alcoholic liver disease to update our knowledge of the topic this year. Our conference will include a lecture on diet and exercise as management and prevention of obesity and fatty liver disease this year. We will also include a lecture on diagnosis and management of benign lesions of the liver given by an expert on this subject. And lastly, there will be a lecture devoted to the use of systemic therapies for hepatocellular carcinoma.

Prices: 

Pre-conference Workshop: USD 150.0, 

Physicians (MD, DO): USD 385.0, 

Non-Physicians (RN, PA, NP): USD 315.0, 

Fellows, Residents, Students: USD 210.0

Speakers: Paul J. Pockros, MD, FACG, Catherine T. Frenette, MD, FAST, AGAF, Timothy J. Davern, MD, Ken Fujioka, MD, Constantine J. Karvellas, MD, SM, FRCPC, FCCM, Kris V. Kowdley, MD, FACP, FACG, FASGE, AGAF, FAASLD, Suthat Liangpunsakul, MD, Yuki Rosenkoetter, PAC, MPAS, Sammy Saab, MD, MPH, AGAF, FAASLD, FACG, Norman L. Sussman, MD, Norah A. Terrault, MD, MPH, John W. Ward, MD 

Time: 12:30 - 11:30

Keep Up to Date with PaperCrowd

Sign up and follow your favorite conferences.

We are no longer accepting conference submissions on PaperCrowd. We apologise for any inconvenience.